ES512093A0 - Una composicion farmaceutica que comprende como ingrediente activo una espiro-(prirrolidin-3,3-indolin)-2,2,5-triona 1,-sustituida. - Google Patents

Una composicion farmaceutica que comprende como ingrediente activo una espiro-(prirrolidin-3,3-indolin)-2,2,5-triona 1,-sustituida.

Info

Publication number
ES512093A0
ES512093A0 ES512093A ES512093A ES512093A0 ES 512093 A0 ES512093 A0 ES 512093A0 ES 512093 A ES512093 A ES 512093A ES 512093 A ES512093 A ES 512093A ES 512093 A0 ES512093 A0 ES 512093A0
Authority
ES
Spain
Prior art keywords
pharmaceutical composition
prirrolidin
triona
stituted
indolin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES512093A
Other languages
English (en)
Other versions
ES8306485A1 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Imperial Chemical Industries Ltd
Original Assignee
Imperial Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imperial Chemical Industries Ltd filed Critical Imperial Chemical Industries Ltd
Publication of ES512093A0 publication Critical patent/ES512093A0/es
Publication of ES8306485A1 publication Critical patent/ES8306485A1/es
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/38—Oxygen atoms in positions 2 and 3, e.g. isatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
ES512093A 1981-05-12 1982-05-11 Una composicion farmaceutica que comprende como ingrediente activo una espiro-(prirrolidin-3,3-indolin)-2,2,5-triona 1,-sustituida. Expired ES8306485A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB8114397 1981-05-12

Publications (2)

Publication Number Publication Date
ES512093A0 true ES512093A0 (es) 1983-06-01
ES8306485A1 ES8306485A1 (es) 1983-06-01

Family

ID=10521723

Family Applications (2)

Application Number Title Priority Date Filing Date
ES512093A Expired ES8306485A1 (es) 1981-05-12 1982-05-11 Una composicion farmaceutica que comprende como ingrediente activo una espiro-(prirrolidin-3,3-indolin)-2,2,5-triona 1,-sustituida.
ES519780A Expired ES8402840A1 (es) 1981-05-12 1983-02-14 Procedimiento para preparar nuevas espiro-(pirrolidin-3,3'-indolin)-2,2'5-trionas 1'-sustituidas.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES519780A Expired ES8402840A1 (es) 1981-05-12 1983-02-14 Procedimiento para preparar nuevas espiro-(pirrolidin-3,3'-indolin)-2,2'5-trionas 1'-sustituidas.

Country Status (25)

Country Link
US (2) US4478847A (es)
EP (1) EP0065407B1 (es)
JP (1) JPS57192314A (es)
KR (1) KR830009775A (es)
AT (1) ATE12113T1 (es)
AU (1) AU561390B2 (es)
CA (1) CA1182823A (es)
DD (1) DD202576A5 (es)
DE (1) DE3262529D1 (es)
DK (1) DK203882A (es)
ES (2) ES8306485A1 (es)
FI (1) FI821579A7 (es)
GR (1) GR75871B (es)
HU (1) HU186016B (es)
IE (1) IE53102B1 (es)
IL (1) IL65604A (es)
MW (1) MW1982A1 (es)
NO (1) NO821557L (es)
NZ (1) NZ200576A (es)
PH (1) PH18101A (es)
PL (1) PL236283A1 (es)
PT (1) PT74876B (es)
ZA (1) ZA822797B (es)
ZM (1) ZM3282A1 (es)
ZW (1) ZW7882A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU566869B2 (en) * 1982-05-11 1987-11-05 Imperial Chemical Industries Plc Spiro (imidazolidine-4,3'-indoline) 2,2',5-triones
GB8331194D0 (en) * 1982-12-20 1983-12-29 Ici Plc Chemical process
JPS60142984A (ja) 1983-12-28 1985-07-29 Kyorin Pharmaceut Co Ltd 新規なスピロピロリジン−2,5−ジオン誘導体およびその製造法
US4567278A (en) * 1984-03-26 1986-01-28 Imperial Chemical Industries Plc Process for racemizing certain spiro compounds
GB8415635D0 (en) * 1984-06-19 1984-07-25 Ici Plc Cyclic amides
MX18021A (es) * 1988-10-18 1993-11-01 Pfizer Pro-farmacos de la 3-acil-2-oxindol-1-carboxamidasanti-inflamatorias
US4900739A (en) * 1988-10-20 1990-02-13 American Home Products Corp. Novel spirosuccinimides as aldose reductase inhibitors and antihyperglycemic agents
US4946858A (en) * 1988-10-20 1990-08-07 American Home Products Corporation Novel spirosuccinimides as aldose reductase inhibitors and antihyperglycemic agents
FR2708606B1 (fr) * 1993-07-30 1995-10-27 Sanofi Sa Dérivés du N-phénylalkylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant.
CA2447984A1 (en) * 2001-09-28 2003-04-03 Mcneil-Ppc, Inc. Dosage forms having an inner core and outer shell with different shapes
US6837696B2 (en) * 2001-09-28 2005-01-04 Mcneil-Ppc, Inc. Apparatus for manufacturing dosage forms
RU2238272C1 (ru) * 2003-05-19 2004-10-20 Пермский государственный университет Способ получения 1-алкил-6,6-диметил-2,4-диоксо-2,3,4,5,6,7-гексагидро-1h-индол-3-спиро-2-( 1-арил-3-ароил-4-гидрокси-5-оксо-2,5-дигидропирролов)
KR101333861B1 (ko) * 2005-05-24 2013-11-28 메르크 세로노 에스. 에이. Crth2 조정자로서 삼환계 스피로 유도체
US20080057023A1 (en) * 2006-08-29 2008-03-06 Chynn Emil W Oxygenated ophthalmic composition
RU2316557C1 (ru) * 2006-10-06 2008-02-10 Государственное образовательное учреждение высшего профессионального образования "Пермский государственный университет" 6,6-диметил-8-оксо-5,6,8,9-тетрагидробензо[f]-пирроло[2,1-альфа]изохинолин-9-спиро-2-(3-ароил-4-гидрокси-1-о-гидроксифенил-5-оксо-2,5-дигидро-1н-пирролы), 6,6-диметил-8-оксо-5,6,8,9-тетрагидробензо[f]пирроло[2,1-альфа]изохинолин-9-спиро-2-(3-бензоил-4-гидрокси-1-о-гидроксифенил-5-оксо-2,5-дигидро-1н-пиррол), проявляющий анальгетическую активность и способ их получения
WO2009026240A1 (en) * 2007-08-17 2009-02-26 Solexel, Inc. Methods for liquid transfer coating of three-dimensional substrates

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4117230A (en) * 1976-10-18 1978-09-26 Pfizer Inc. Hydantoin derivatives as therapeutic agents
US4177230A (en) * 1978-06-02 1979-12-04 The United States Of America As Represented By The Secretary Of The Air Force Process for producing reaction sintered silicon nitride of increased density
US4307108A (en) * 1979-12-26 1981-12-22 Pfizer Inc. Method for lowering sorbitol levels using spiro-imides

Also Published As

Publication number Publication date
PT74876B (en) 1983-12-07
ZW7882A1 (en) 1983-11-30
NO821557L (no) 1982-11-15
IL65604A (en) 1986-12-31
GR75871B (es) 1984-08-02
FI821579L (fi) 1982-11-13
EP0065407A3 (en) 1983-03-16
PT74876A (en) 1982-06-01
FI821579A0 (fi) 1982-05-05
ZA822797B (en) 1983-07-27
EP0065407A2 (en) 1982-11-24
NZ200576A (en) 1984-11-09
AU561390B2 (en) 1987-05-07
ATE12113T1 (de) 1985-03-15
ES8306485A1 (es) 1983-06-01
JPS57192314A (en) 1982-11-26
CA1182823A (en) 1985-02-19
IE820928L (en) 1982-11-12
EP0065407B1 (en) 1985-03-13
DD202576A5 (de) 1983-09-21
PL236283A1 (en) 1983-09-12
ZM3282A1 (en) 1982-12-21
ES519780A0 (es) 1984-03-01
AU8299482A (en) 1982-11-18
DE3262529D1 (en) 1985-04-18
DK203882A (da) 1982-11-13
IE53102B1 (en) 1988-06-22
HU186016B (en) 1985-05-28
US4478847A (en) 1984-10-23
KR830009775A (ko) 1983-12-23
MW1982A1 (en) 1984-02-08
FI821579A7 (fi) 1982-11-13
PH18101A (en) 1985-03-20
US4523021A (en) 1985-06-11
ES8402840A1 (es) 1984-03-01

Similar Documents

Publication Publication Date Title
ATE12113T1 (de) Aktive pharmazeutische spirosuccinimidderivate.
PT97689A (pt) Processo para a preparacao de composicoes farmaceuticas incorporando como ingrediente activo isoxazol-4-carboxilamida e hidroxialquilideno-cianoacetamida
ES2055860T3 (es) Derivados 2-aminopirimidinona.
DE69519385D1 (de) Chinazolinon-arzneimittel sowie deren verwendung
ATE15596T1 (de) Pharmazeutische mittel.
NO154842C (no) Analogifremgangsmaate for fremstilling av farmasoeytisk aktive 1'-substituerte spiro-(imidazolidin-4,3'-indolin)-2,2', 5-trioner.
OA08023A (fr) Nouvelles bis-(4-aminophényl)-sulfones substituées, leur préparation et leur utilisation en tant que médicament.
EP0321968A3 (en) Compounds active on the cardiovascular system
NO833528L (no) Fremgangsmaate for fremstilling av terapeutisk aktive fenyl-cyklobutan-derivater
DE3584608D1 (de) Amidabkoemmlinge.
ATE230727T1 (de) Alpha-substituierte heterozyklische benzylderivate, zwischenverbindungen zu ihrer herstellung und pestizide die diese als aktiver bestandteil enthalten
ATE11049T1 (de) Aktive pharmazeutische spirohydantoinderivate.
ATE18203T1 (de) (-)-15-deoxyspergualin, seine herstellung und arzneimittel mit diesem wirkstoff.